View Older Stories View More Recent Stories

May 8, 2024 09:00AM Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference
May 2, 2024 09:00AM Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
Apr 10, 2024 09:02AM Amylyx Pharma (AMLX) Announces Interim Data From Ongoing Phase 2 HELIOS Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
Apr 10, 2024 09:00AM Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Synd
Apr 8, 2024 10:04AM AMLX DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action – AMLX
Apr 8, 2024 09:02AM Amylyx Pharmaceuticals (AMLX) to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024
Apr 8, 2024 09:00AM Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024
Apr 4, 2024 07:02AM Amylyx Pharmaceuticals (AMLX) to Remove RELYVRIO/ALBRIOZA from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy
Apr 4, 2024 07:00AM Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy
Mar 31, 2024 12:54PM ROSEN, A LEADING LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action – AMLX
Mar 25, 2024 06:17PM ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMLX
Mar 15, 2024 06:27PM ROSEN, LEADING INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMLX
Mar 14, 2024 09:01AM Amylyx Pharmaceuticals (AMLX) Appoints Bernhardt Zeiher to its Board
Mar 14, 2024 09:00AM Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors
Mar 8, 2024 07:00AM Amylyx Pharmaceuticals (AMLX) Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
Mar 8, 2024 07:00AM Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
Mar 7, 2024 05:40PM ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMLX
Mar 3, 2024 03:07PM ROSEN, NATIONAL TRIAL COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMLX
Feb 23, 2024 04:05PM Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Feb 22, 2024 07:00AM Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
Feb 16, 2024 04:28PM ROSEN, LEADING INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMLX
Feb 15, 2024 04:05PM Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
Feb 15, 2024 09:00AM Amylyx Pharmaceuticals to Present Updates on its AMX0114 and RELYVRIO® Programs in ALS at the 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference
Feb 8, 2024 09:00AM Amylyx Pharmaceuticals Announces Completion of Enrollment in HELIOS, a Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome
Dec 22, 2023 09:00AM Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy (PSP)
Dec 4, 2023 09:00AM Amylyx Pharmaceuticals Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS
Nov 29, 2023 05:15PM Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 28, 2023 07:01AM Amylyx Pharmaceuticals (AMLX) Appoints Camille L. Bedrosian, MD, as Chief Medical Officer
Nov 28, 2023 07:00AM Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer
Nov 27, 2023 09:00AM RELYVRIO® and AMX0114 Data to be Presented at 34th International Symposium on ALS/MND
Nov 21, 2023 09:00AM Amylyx Pharmaceuticals to Participate at the 6th Annual Evercore ISI HealthCONx Conference
Nov 9, 2023 07:00AM Amylyx Pharmaceuticals Reports Third Quarter 2023 Financial Results
Nov 2, 2023 09:00AM Amylyx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 9, 2023
Oct 19, 2023 09:00AM Amylyx Pharmaceuticals to Present Clinical Trial Design of ORION, a Phase 3 Global Study of AMX0035 in Progressive Supranuclear Palsy (PSP), at the Neuro2023 PSP and CBD International Research Symposi
Oct 13, 2023 07:45AM Amylyx Pharmaceuticals (AMLX) Receives Negative CHMP Opinion on its MAA for AMX0035 for Treatment of ALS in the European Union Following Re-Examination Process
Oct 13, 2023 07:45AM Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process
Oct 10, 2023 09:12AM Amylyx Pharmaceuticals (AMLX) Announces Publication of Survival Analysis Comparing CENTAUR to Historical Clinical Trial Control
Oct 10, 2023 09:12AM Amylyx Pharmaceuticals Announces Publication of Survival Analysis Comparing CENTAUR to Historical Clinical Trial Control
Oct 2, 2023 09:00AM RELYVRIO® and AMX0114 Data to be Presented at 22nd Annual Northeast ALS Consortium (NEALS) Meeting
Sep 5, 2023 09:00AM Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
Aug 10, 2023 04:01PM Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results
Aug 3, 2023 04:05PM Amylyx Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 10, 2023
Jul 12, 2023 09:00AM Amylyx Pharmaceuticals to Host Virtual Webcast on AMX0035 Progressive Supranuclear Palsy (PSP) Program
Jun 23, 2023 08:14AM Amylyx Pharmaceuticals (AMLX) Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union
Jun 23, 2023 08:14AM Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union
Jun 15, 2023 09:04AM Amylyx Pharmaceuticals (AMLX) Completes Negotiation Process and Signs Letter of Intent with the pCPA for ALBRIOZA for the Treatment of ALS
Jun 15, 2023 09:00AM Amylyx Pharmaceuticals Completes Negotiation Process and Signs Letter of Intent with the pCPA for ALBRIOZA™ for the Treatment of ALS
Jun 6, 2023 09:00AM Amylyx Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
May 30, 2023 08:00AM Amylyx Pharmaceuticals (AMLX) Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European Union
May 30, 2023 08:00AM Amylyx Pharmaceuticals Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European Union
View More Recent Stories View Older Stories